+86 137 2013 4139
+86 137 2013 4139
| CAS: | 1903008-80-9 | Cat No: | JKN03178 | Purity: | 98% |
Note: All products of the company are for scientific research only, and do not provide products and services for any individual
Product Description
| CAS | 1903008-80-9 | Cat No | JKN03178 | |
| Name | Lazertinib | |||
| Synonyms | Lazertinib | |||
| Smiles | CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC | |||
| Chemical Name | N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide | |||
| Formula | C30H34N8O3 | MWt | 554.6 | |
| Purity | 98% | Storage | Store at 4--8℃ | |
| Description | Lazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. It was approved by the FDA on August 19, 2024. Lazertinib is used alone or in combination with other chemotherapeutic agents. | |||
Product Documents
Menu
Contact Us
Tel: +86 137 2013 4139
E-mail: orders@jknbiochem.com
Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China
Get In Touch
Get In Touch
